GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (FRA:PGP) » Definitions » Accounts Receivable

Progenics Pharmaceuticals (FRA:PGP) Accounts Receivable : €5.60 Mil (As of Mar. 2020)


View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Progenics Pharmaceuticals's accounts receivables for the quarter that ended in Mar. 2020 was €5.60 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Progenics Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2020 was 90.41.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Progenics Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2020 was €-0.35.


Progenics Pharmaceuticals Accounts Receivable Historical Data

The historical data trend for Progenics Pharmaceuticals's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Accounts Receivable Chart

Progenics Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.24 4.18 3.11 3.34 14.38

Progenics Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.68 8.49 4.46 14.38 5.60

Progenics Pharmaceuticals Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Progenics Pharmaceuticals Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Progenics Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2020 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=5.602/5.654*91
=90.41

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Progenics Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Progenics Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2020 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(26.726+0.75 * 5.602+0.5 * 0-61.297
-0-0)/86.596
=-0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Progenics Pharmaceuticals Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Progenics Pharmaceuticals (FRA:PGP) Business Description

Traded in Other Exchanges
N/A
Address
One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007
Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Progenics Pharmaceuticals (FRA:PGP) Headlines

From GuruFocus

PGP Statement on SEC Settlement

By sperokesalga sperokesalga 06-16-2023